Empagliflozin: a potential anticancer drug
Abstract Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is a highly effective and well-tolerated antidiabetic drug. In addition to hypoglycemic effects, empagliflozin has many other effects, such as being hypotensive and cardioprotective. It also has anti-inflammatory and antioxi...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Springer
2023-07-01
|
| Schriftenreihe: | Discover Oncology |
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.1007/s12672-023-00719-x |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|